

April 18, 2007



Ceapro Launches Superior Care for Man's Best Friend in U.S. Market

Proprietary Products Proven to Protect Pets

LIHUE KAUAI, HI, April 18 /PRNewswire-FirstCall/ - CEAPRO Inc. ("CEAPRO") (TSX-V CZO) today announced the U.S. launch of Ceapro Dermatology pet care products, approved by and sold through veterinarians. Ceapro is capitalizing on its animal health product successes elsewhere by entering the U.S. market - a significant thrust as the American market constitutes over 70% of global animal health sales.

Ceapro Dermatology products are unique in using 100% bioavailable oat actives(TM). Unlike most other oat products, all our patented active ingredients are fully soluble, providing immediate penetration of active components. Importantly, Ceapro's patented processes and analytical procedures produce standardized extracts, guaranteeing product consistency and proven clinical performance, so offering over-the-counter reliability for pets. The all natural shampoo, ear cleaner, and dermal complex are formulated to naturally improve pet health and reduce the need for steroid treatments.

Ceapro's full range of veterinary therapeutics provides an integrated approach to health in animals. The products, which help reduce the incidence of skin and ear disease while minimizing the need for active treatment, are available exclusively through veterinarians. Hence the timing and location of the launch: to over 300 veterinary practitioners attending the North American Veterinary Dermatology Forum in Hawaii from 18-22 April, 2007. The rollout is supported by a dedicated website: www.ceaproderm.com.

To ensure veterinarians nationwide are fully informed of the technical advances of Ceapro Dermatology's products, the Company will sell through well-connected, experienced distributors with established access to veterinarians throughout the U.S. This mirrors the successful marketing of Ceapro's veterinary therapeutics throughout Europe, Asia, Asia-Pacific, and Canada.

Ceapro Dermatology products will also be available online through www.ceaproderm.com, with a veterinary rebate incentive program.

About Ceapro Inc.

Ceapro Inc is a Canadian growth-stage biotechnology company. Ceapro's core technology is the extraction of functional, active ingredients from plants and other renewable resources. We add further value to our extracts by manufacturing medical and therapeutic products, and by supporting the use of our extracts in products for human and animal health. We have also introduced health and wellness services employing our CeaProve(R) diagnostic technology. Our most recent initiative is the creation of Ceapro BioEnergy Inc. (CBE), a

wholly-owned subsidiary to utilize Ceapro's proprietary technology for the production of ethanol and value-added products. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit our website at www.ceapro.com.

The TSX-Venture has neither approved nor disapproved of the information contained herein and does not accept responsibility for the adequacy or accuracy of this release.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

SOURCE Ceapro Inc.